RESMED INC

Capital Structure and Liquidity ResMed maintains a strong liquidity position with a current ratio of 3.06 and a debt-to-equity ratio of 0.04, indicating a conservative capital structure. The company's cash and equivalents of $1.42 billion and short-term debt of $259.9 million suggest ample liquidity to meet short-term obligations. The low liquidity risk is further supported by a robust operating cash flow of $797.1 million and free cash flow of $725.6 million. ### Profitability and Returns ResMed's profitability is robust, with a return on equity (ROE) of 11.73% and a return on assets (ROA) of 8.72%, both exceeding the industry median for advanced medical equipment and technology firms. The company's operating margin of 34.0% (calculated from operating income of $938.2 million on revenue of $2.76 billion) reflects efficient cost management and pricing power. ### Segments and Geographic Exposure ResMed operates two primary segments: Sleep and Breathing Health and Residential Care Software. The Sleep and Breathing Health segment is the core revenue driver, with a significant portion of revenue concentrated in the United States and other developed markets. The company's geographic exposure is diversified, with revenue split between the U.S. and the rest of the world, though the U.S. remains the largest market. ### Growth Trajectory ResMed's growth trajectory is supported by a strong revenue base of $2.76 billion and a consistent history of revenue growth. The company's outlook for the current fiscal year (FY) and the next FY is positive, with a focus on expanding its SaaS offerings and enhancing its connected care solutions. The company's capital expenditure of $71.5 million is modest, indicating a focus on maintaining existing operations rather than aggressive expansion. ### Risk Factors ResMed faces medium dilution risk, with source documents mentioning potential dilution or offering risks. The company's risk assessment highlights the need to monitor dilution potential, particularly in the context of its equity investments and marketable securities. The company's exposure to non-marketable and marketable equity securities is managed through quarterly impairment assessments and foreign currency translation adjustments. ### Recent Events Recent filings include updates on interim reporting, government grants, and hedge accounting improvements, reflecting the company's commitment to compliance and financial transparency. The company has also disclosed changes in its equity investments, including impairments and unrealized gains/losses, which are critical for assessing the health of its investment portfolio.